FDA Approves AstraZeneca COPD Medicine

September 14, 2017

Pharmaceutical Executive

AstraZeneca announced that the FDA has approved its SYMBICORT (budesonide/formoterol fumarate dihydrate) inhalation aerosol 160/4.5 micrograms to decrease exacerbations of chronic obstructive pulmonary disease (COPD).

SYMBICORT 160/4.5 works to maintain treatment of airflow obstruction in patients with COPD-including chronic bronchitis and/or emphysema-and to lessen COPD exacerbations.

SYMBICORT has not been indicated for the relief of acute bronchospasm.

For mor information, read the prescribing information, boxed warning, and medication guide here.

Related Content:

News | Regulatory